Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OTQ923

Phase 1Biologic

OTQ923 is one of 50 biologic programs targeting Sickle Cell Disease. It is currently in Phase 1.

1

Indications

2

Total Trials

1

Active Trials

49

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sickle Cell DiseaseActive, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

98 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Ritalin

Aqvesme

AAgios Pharmaceuticals, Inc.

Toradol

JJavelin Pharmaceuticals

Wayrilz

GGenzyme, a Sanofi Company

Fludara

Cellcept

PIASKY

Rapamune

PPrism Pharmaceuticals

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2039

Phase 1Active, not recruiting

Sickle Cell Disease

NCT06155500

Clinical

Trials by Indication[1]

Sickle Cell Disease2 trials

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

Terminated· Novartis logo

Novartis·Phase 1·NCT04443907·4 enrolled

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06155500·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for OTQ923. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OTQ923 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OTQ923. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Novartis

Related News